|
|
Vaccine Detail
|
PD-L1/IDO Peptide Vaccine IO102-103 |
| Vaccine Information |
- Vaccine Name: PD-L1/IDO Peptide Vaccine IO102-103
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: IO102/IO103 peptide and PD-L1 long1 peptide (NCIT_C148154; NCT03047928)
- Immunization Route: Other
- Description: This peptide vaccine is composed of IO103, a peptide derived from the tumor-associated antigen (TAA) programmed cell death-1 ligand 1 (PD-L1), IO102, the 21-mer peptide vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO), and the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. (NCIT_C148154) Both IDO and PD-L1 reactive CD8 T cells are cytotoxic and can kill cancer cells and immune regulatory cells in vitro. Thus boosting specific T cells that recognize immune regulatory proteins such as IDO and PD-L1 may directly modulate immune regulation. The the programmed death 1 (PD-1) regulatory antibody Nivolumab may further help treat patients with metastatic melanoma. (NCT03047928)
|
| Host Response |
|
|
| References |
NCIT_C148154: PD-L1/IDO Peptide Vaccine IO102-103 [https://ncithesaurus.nci.nih.gov/ncitbrowser/pages/home.jsf]
NCT03047928: Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma [https://clinicaltrials.gov/study/NCT03047928]
|
|
